Precision BioSciences Inc (DTIL) - Net Assets
Based on the latest financial reports, Precision BioSciences Inc (DTIL) has net assets worth $92.25 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($154.42 Million) and total liabilities ($62.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check DTIL asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $92.25 Million |
| % of Total Assets | 59.74% |
| Annual Growth Rate | N/A |
| 5-Year Change | 1.18% |
| 10-Year Change | N/A |
| Growth Volatility | 118.12 |
Precision BioSciences Inc - Net Assets Trend (2016–2025)
This chart illustrates how Precision BioSciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore Precision BioSciences Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Precision BioSciences Inc (2016–2025)
The table below shows the annual net assets of Precision BioSciences Inc from 2016 to 2025. For live valuation and market cap data, see DTIL stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $92.25 Million | +63.58% |
| 2024-12-31 | $56.39 Million | +198.99% |
| 2023-12-31 | $18.86 Million | -68.79% |
| 2022-12-31 | $60.43 Million | -33.71% |
| 2021-12-31 | $91.17 Million | +105.22% |
| 2020-12-31 | $44.42 Million | -67.88% |
| 2019-12-31 | $138.31 Million | +246.13% |
| 2018-12-31 | $39.96 Million | +251.54% |
| 2017-12-31 | $-26.37 Million | -455.25% |
| 2016-12-31 | $-4.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Precision BioSciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 51017900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $620.43 Million | 672.57% |
| Total Equity | $92.25 Million | 100.00% |
Precision BioSciences Inc Competitors by Market Cap
The table below lists competitors of Precision BioSciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Inveo Yatirim Holding AS
IS:INVEO
|
$170.67 Million |
|
Bonei Hatichon Civil Engineering and Infrastructures Ltd
TA:BOTI
|
$170.68 Million |
|
DNF Co.Ltd
KQ:092070
|
$170.88 Million |
|
United Security Bancshares
NASDAQ:UBFO
|
$171.01 Million |
|
Kyungbangco.Ltd
KO:000050
|
$170.54 Million |
|
Jyoti Structures Limited
NSE:JYOTISTRUC
|
$170.53 Million |
|
Protalix Biotherapeutics Inc
NYSE MKT:PLX
|
$170.49 Million |
|
Aumann AG
XETRA:AAG
|
$170.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Precision BioSciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 56,393,000 to 92,248,000, a change of 35,855,000 (63.6%).
- Net loss of 46,609,000 reduced equity.
- New share issuances of 94,944,000 increased equity.
- Other factors decreased equity by 12,480,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-46.61 Million | -50.53% |
| Share Issuances | $94.94 Million | +102.92% |
| Other Changes | $-12.48 Million | -13.53% |
| Total Change | $- | 63.58% |
Book Value vs Market Value Analysis
This analysis compares Precision BioSciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.01x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.28 | $7.28 | x |
| 2017-12-31 | $-23.51 | $7.28 | x |
| 2018-12-31 | $24.45 | $7.28 | x |
| 2019-12-31 | $98.80 | $7.28 | x |
| 2020-12-31 | $25.61 | $7.28 | x |
| 2021-12-31 | $46.60 | $7.28 | x |
| 2022-12-31 | $20.63 | $7.28 | x |
| 2023-12-31 | $4.91 | $7.28 | x |
| 2024-12-31 | $8.19 | $7.28 | x |
| 2025-12-31 | $7.19 | $7.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Precision BioSciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -50.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -136.03%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.67x
- Recent ROE (-50.53%) is above the historical average (-100.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -117.62% | 0.07x | 0.00x | $-7.78 Million |
| 2017 | 0.00% | -325.45% | 0.09x | 0.00x | $-18.47 Million |
| 2018 | -115.21% | -423.02% | 0.08x | 3.47x | $-50.03 Million |
| 2019 | -67.15% | -417.65% | 0.09x | 1.70x | $-106.71 Million |
| 2020 | -245.37% | -448.86% | 0.16x | 3.38x | $-113.45 Million |
| 2021 | -33.57% | -26.49% | 0.55x | 2.32x | $-39.72 Million |
| 2022 | -184.73% | -444.80% | 0.11x | 3.94x | $-117.68 Million |
| 2023 | -325.11% | -125.84% | 0.30x | 8.47x | $-63.21 Million |
| 2024 | 12.71% | 10.43% | 0.50x | 2.42x | $1.53 Million |
| 2025 | -50.53% | -136.03% | 0.22x | 1.67x | $-55.83 Million |
Industry Comparison
This section compares Precision BioSciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Precision BioSciences Inc (DTIL) | $92.25 Million | 0.00% | 0.67x | $170.56 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalent… Read more